Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-10-08
2000-12-05
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514908, 530309, 530311, 530324, 530327, 530328, A61K 3800
Patent
active
061567256
ABSTRACT:
A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be useful in preventing, inhibiting, or modulating the hypersecretion of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P. The composition may suitably comprise, consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin, VIP, bombesin, and Substance P. Also provided is a method of treatment for humans or other animals suffering from cancer, the method comprising administering a therapeutically effective dose of the pharmaceutical composition so as to kill or inhibit the multiplication of cancer cells. The method of treatment may be particularly useful in the treatment of cancers of the colon and rectum. Also provided is a method of treatment for humans or animals having hypersecretion or modulation of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P.
REFERENCES:
patent: 5273963 (1993-12-01), Moody
patent: 5434132 (1995-07-01), Rozengurt
Liebow, C., et al. "Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase." Proc. of the Nat. Acad. of Sciences of the USA, vol. 86, No. 6 (1989)pp. 2003-2007.
Pinski, J., et al. "Inhibition of Growth of MKN45 Human Gastric-Carcinoma Xenografts in Nude Mice by Treatment with Bombesin/Gastrin-Releasing-Peptide Antagonist (RC-3095) and Somatostatin Analogue RC-160." International Journal of Cancer, vol. 57, No. 4 (1994) pp. 574-580.
E. Bombardieri, et al., "Somatostatin Receptor Imaging of Small Cell Lung Cancer . . . Scintigraphy," European Journal of Cancer, vol. 31A, No. 2, pp.184-188, 1995.
J. Pinski, et al., "Somatostatin Analogues And Bombesin/Gastrin . . . In Vitro And In Vivo," Peptide Analogues In Glioblastomas, vol. , pp.5895-5901, (1994).
P.A. Bunn, Jr., et al., "Effects of Neuropeptide Analogues on . . . Cancer Cell Lines," Cancer Research 54, pp. 3602-3610, Jul. 1, 1994.
G. Lilling, et al., "Inhibition of Human Neuroblastoma . . . VIP Antagonist," Journal of Molecular Neuroscience, vol. 5, 1994/1995, pp. 231-239.
H. Reile, et al., "Characterization of High-Affinity Receptors for Bombesin/Gastrin Releasing . . . By Tumor Cells," The Prostate 25:29-38, (1994).
I. Virgolini, M.D., et al., "Vasoactive Intestinal Peptide-Receptor . . . Endocrine Tumors," The New England Journal of Medicine, vol. 331, No. 17, pp. 1116-1121, Oct. 27, 1994.
K. Frank-Raue, et al., "Somatostatin Receptor Imaging in Persistent Medullary Thyroid Carcinoma," Clinical Endocrinology (1995) 42, pp. 31-37.
Gabor Halmos, et al., "Characterization of Bombesin/Gastrin-Releasing Peptide . . . Gastric Cancer," Cancer Letters 85 (1994), pp. 111-118.
Antal Orosz, et al., "New Short-Chain Analogs of Substance-P . . . Cells In Vitro and In Vivo," Int. J. Cancer, 60, pp. 82-87, (1995).
Karoly Szepeshazi, et al., "Combination of Nitrosamine-Induced . . . Bombesin/GRP Antagonist," Int'l. Journal of Pancreatology, vol. 16, Nos. 2-3, pp. 141-149, Oct.-Dec. 1994.
P. Heinz-Erian, et al., "Characterization of a New Group of Substituted Substance P . . . Antagonists," Abstracts of Papers, pp. 1455, May 1986.
Tim Mosmann, "Rapid Colorimetric Assay for Cellular Growth and . . . Cytotoxicity Assays," Journal of Immunological Methods, 65, (1983), pp. 55-63.
I. Zachary, et al., "Bombesin, Vasopressin, and Endothelin Rapidly Stimulate . . . 3T3 Cells," Proc. Natl. Acad. Sci. USA, vol. 88, pp. 4577-4581, Jun. 1991.
I. Gozes, et al., "Vasoactive Intestinal Peptide Potentiates Sexual Behavior . . . . Antagonist," Endocrinology, vol. 125, No. 6, pp. 2945-2949, 1989.
P. Woll, et al., "[D-ARG.sup.1,D-PHE.sup.5,D-TRP.sup.7,9, LEU.sup.11 ] Substance P, A Potent Bombesin . . . In Vitro," Proc. Natl. Acad. Sci. USA, vol. 85, pp. 1859-1863, Mar. 1988.
M. Jaggi, et al., "New, Sensitive and Specific Elisa for Detection . . . Supernatants," Journal of Immunoassay, 15(2), pp. 129-146 (1994).
K. Gulya, et al., "Cyclic Somatostatin Octapeptide Analogues With High . . . Opioid Receptors," Life Sciences, vol. 38, No. 24, pp.2221-2229, 1986.
M. Brown, et al., "Somatostatin: Analogs With Selected Biological Activities," Science, vol. 196, pp.1467-1469, (1977).
J. T. Pelton, et al., "Design and Synthesis of Conformationally Constrained Somatostatin . . . Receptors," J. Med. Chem. 1986, 29, pp. 2370-2375.
M. Jaggi, et al., "Establishment of Tumorigenic Cell Lines From Biopsies . . . Adenocarcinomas," Journal of Basic & Applied Biomedicine (1995) 3 (4), pp. 27-35.
Frucht et al., Cancer Res., 52(5), 1114-22, 1992.
Jaggi Manu
Mukherjee Rama
Delacroix-Muirheid C.
National Institute of Immunology
Tsang Cecilia J.
LandOfFree
Drug for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-961779